News

Phase 3 BREAKWATER finds encorafenib+cetuximab+FOLFIRI improves PFS and response in first-line BRAF V600E metastatic colorectal cancer.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed how recent trial findings are affecting their treatment of newly diagnosed multiple myeloma.

Cancer survival hits 70% as early screening and immunotherapy advance—yet survivorship needs and Indigenous disparities demand urgent action.

The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the EXCALIBER-RRMM trial.

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and infusion reactions while maintaining efficacy.

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion–positive NSCLC, signaling a potential new standard and expanding genomic testing.

Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and smarter caregiver support.

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

FDA grants orphan drug designation to HCB101 for gastric cancer; early trials suggest safer CD47 checkpoint blockade with promising tumor control in advanced settings.

ASH updates AYA ALL care: pediatric-inspired frontline therapy, MRD-driven decisions, targeted TKIs, and immunotherapy-led relapse treatment.

BTK inhibitors or time-limited venetoclax combos? Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life.

Nivolumab–ipilimumab extends survival in unresectable HCC, but US cost-effectiveness falls short; dosing changes or price cuts may shift value.

Dr Manmeet Ahluwalia explores how precision oncology and targeted therapies are transforming brain metastases care, extending survival from months to years.

Cancer breakthroughs surge, but trials and novel therapies stay out of reach for many. See how community care, policy, and design can close gaps.

New ASCO Living Guidelines on prostate cancer emphasize first-line therapies, bone protection, and the growing role of genetic testing.

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS following transplant.

Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma.

FDA accepts Ameluz PDT sNDA for superficial basal cell carcinoma, with strong phase 3 clearance data and a September 2026 decision deadline.

FDA approves Optune Pax, a wearable tumor treating fields device, to pair with GnP chemo in locally advanced pancreatic cancer, extending survival and delaying pain.

G6PD deficiency links to higher remission and longer survival in AML patients on venetoclax plus azacitidine, suggesting a simple biomarker to guide treatment.

Global phase 3 trial tests safusidenib maintenance after chemoradiotherapy, aiming to delay recurrence and improve survival in IDH1-mutant astrocytoma.

FDA fast-tracks irpagratinib for FGF19+ advanced liver cancer, with early trials showing strong response rates and ongoing combo study momentum.

A recent white paper determines that the link between GLP-1 agonist inhibitors and thyroid cancer is unconvincing.

FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable safety.

Brittany Dulmage, MD, discusses why a popular ingredient in hair, skin, and nails vitamins may not be a safe option for patients undergoing cancer treatment.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.